REYATAZ en es it fr

REYATAZ Brand names, REYATAZ Analogs

REYATAZ Brand Names Mixture

  • No information avaliable

REYATAZ Chemical_Formula



REYATAZ fda sheet


REYATAZ msds (material safety sheet)

REYATAZ Synthesis Reference

No information avaliable

REYATAZ Molecular Weight

704.856 g/mol

REYATAZ Melting Point

No information avaliable

REYATAZ H2O Solubility

Free base slightly soluble (4-5 mg/mL)





REYATAZ Dosage Forms

Capsule (100 mg, 150 mg, or 200 mg)

REYATAZ Indication

For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection.

REYATAZ Pharmacology

Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). It is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Atazanavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

REYATAZ Absorption

Atazanavir is rapidly absorbed with a Tmax of approximately 2.5 hours. Administration of atazanavir with food enhances bioavailability and reduces pharmacokinetic variability

REYATAZ side effects and Toxicity

No information avaliable

REYATAZ Patient Information

REYATAZ Organisms Affected

Human immunodeficiency virus